MCID: HYP835
MIFTS: 38

Hypothalamic Obesity

Categories: Endocrine diseases, Metabolic diseases, Rare diseases

Aliases & Classifications for Hypothalamic Obesity

MalaCards integrated aliases for Hypothalamic Obesity:

Name: Hypothalamic Obesity 20
Babinski-Froelich Syndrome 20
Adiposogenital Dystrophy 20
Froelich's Adiposity 20
Froelich's Syndrome 20
Froehlich Syndrome 20
Adiposodysgenesis 20

Classifications:



Summaries for Hypothalamic Obesity

GARD : 20 Hypothalamic obesity refers to obesity that is caused by physical or inborn damage to the hypothalamus. The hypothalamus is part of the brain that makes hormones that control specific body functions such as sleep, body temperature, and hunger. It also makes hormones that control other organs in the body, especially the pituitary gland. The symptoms of hypothalamic obesity vary by the cause and include uncontrollable hunger, rapid, excessive weight gain, and a low metabolic rate. If the pituitary gland is involved, symptoms may include small underdeveloped testes in males and delayed puberty. This condition most often occurs because of injury to the hypothalamus due to a tumor, swelling in the brain, brain surgery, or head trauma. The diagnosis is made by physical examination and review of the symptoms. There is no cure for hypothalamic obesity. Treatment involves a combination of surgery, medications, and nutritional and lifestyle counseling. The long-term outlook for people with this condition is dependent on weight loss and management.

MalaCards based summary : Hypothalamic Obesity, also known as babinski-froelich syndrome, is related to craniopharyngioma and pituitary hormone deficiency, combined, 2. An important gene associated with Hypothalamic Obesity is INS (Insulin), and among its related pathways/superpathways are Prolactin Signaling Pathway and AMP-activated Protein Kinase (AMPK) Signaling. The drugs Octreotide and Antineoplastic Agents, Hormonal have been mentioned in the context of this disorder. Affiliated tissues include pituitary, hypothalamus and brain, and related phenotypes are adipose tissue and homeostasis/metabolism

Related Diseases for Hypothalamic Obesity

Diseases related to Hypothalamic Obesity via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 195)
# Related Disease Score Top Affiliating Genes
1 craniopharyngioma 30.5 LEPR INS IGF1
2 pituitary hormone deficiency, combined, 2 30.1 IGF1 GHRH
3 hypothalamic disease 30.0 INS GHRH
4 secondary adrenal insufficiency 30.0 INS IGF1
5 hypopituitarism 29.7 LEP INS IGF1 GHRH
6 hyperprolactinemia 29.6 INS IGF1 GHRH
7 pituitary gland disease 29.6 INS IGF1 GHRH
8 hyperinsulinism 29.5 RETN LEPR LEP INS IGF1
9 bone resorption disease 29.4 LEP INS IGF1
10 body mass index quantitative trait locus 11 29.3 RETN LEPR LEP INS IGF1 GHRH
11 genetic obesity 29.1 LEPR LEP IGF1
12 hypothyroidism 29.1 RETN LEP INS IGF1 GHRH
13 apnea, obstructive sleep 29.1 RETN LEP INS IGF1
14 prader-willi syndrome 29.0 RETN LEPR LEP INS IGF1
15 fatty liver disease 28.8 RETN LEPR LEP INS
16 liver disease 28.8 RETN LEPR LEP INS
17 leptin deficiency or dysfunction 28.8 RETN LEPR LEP INS IGF1 GHRH
18 sleep apnea 28.4 RETN LEPR LEP INS IGF1
19 glucose intolerance 28.4 RETN LEPR LEP INS IGF1
20 diabetes mellitus 28.4 RETN LEPR LEP INS IGF1
21 non-alcoholic fatty liver disease 28.4 RETN LEPR LEP INS IGF1
22 type 2 diabetes mellitus 28.3 RETN LEPR LEP INS IGF1
23 froelich syndrome 11.3
24 body mass index quantitative trait locus 9 10.6
25 body mass index quantitative trait locus 8 10.6
26 body mass index quantitative trait locus 4 10.6
27 body mass index quantitative trait locus 10 10.6
28 body mass index quantitative trait locus 7 10.6
29 body mass index quantitative trait locus 12 10.6
30 body mass index quantitative trait locus 14 10.6
31 body mass index quantitative trait locus 18 10.6
32 body mass index quantitative trait locus 19 10.6
33 deficiency anemia 10.2
34 myotonic dystrophy 10.2
35 diabetes insipidus 10.2
36 kearns-sayre syndrome 10.2
37 meningitis 10.2
38 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 10.1 INS IGF1
39 acidophil adenoma 10.1 INS IGF1
40 somatostatinoma 10.1 INS GHRH
41 bleeding disorder, platelet-type, 14 10.1 RETN INS
42 potter's syndrome 10.1 INS IGF1
43 hydrocephalus 10.1
44 marasmus 10.1 INS IGF1
45 diabetic encephalopathy 10.1 INS IGF1
46 pituitary apoplexy 10.1 INS IGF1
47 carcinoid syndrome 10.1 IGF1 GHRH
48 empty sella syndrome 10.1 INS IGF1
49 hormone producing pituitary cancer 10.1 IGF1 GHRH
50 isolated growth hormone deficiency type iii 10.1 IGF1 GHRH

Graphical network of the top 20 diseases related to Hypothalamic Obesity:



Diseases related to Hypothalamic Obesity

Symptoms & Phenotypes for Hypothalamic Obesity

MGI Mouse Phenotypes related to Hypothalamic Obesity:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 adipose tissue MP:0005375 9.95 GHRH HSD17B1 IGF1 INS LEP LEPR
2 homeostasis/metabolism MP:0005376 9.87 GHRH HSD17B1 IGF1 INS LEP LEPR
3 endocrine/exocrine gland MP:0005379 9.85 GHRH HSD17B1 IGF1 INS LEP LEPR
4 immune system MP:0005387 9.73 GHRH IGF1 INS LEP LEPR RETN
5 liver/biliary system MP:0005370 9.55 GHRH INS LEP LEPR RETN
6 reproductive system MP:0005389 9.43 GHRH HSD17B1 IGF1 INS LEP LEPR
7 skeleton MP:0005390 9.1 GHRH HSD17B1 IGF1 INS LEP LEPR

Drugs & Therapeutics for Hypothalamic Obesity

Drugs for Hypothalamic Obesity (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 19)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
2 Antineoplastic Agents, Hormonal Phase 4
3 Gastrointestinal Agents Phase 4
4
Exenatide Approved, Investigational Phase 3 141758-74-9 15991534
5
Glucagon Approved Phase 3 16941-32-5
6 Hormones Phase 3
7 Anti-Obesity Agents Phase 3
8 Hypoglycemic Agents Phase 3
9 Hormone Antagonists Phase 3
10 Incretins Phase 3
11 Glucagon-Like Peptide 1 Phase 3
12
Metformin Approved Phase 2 657-24-9 14219 4091
13
Diazoxide Approved Phase 2 364-98-7 3019
14
Oxytocin Approved, Vet_approved Phase 2 50-56-6 439302 53477758
15 Vasodilator Agents Phase 2
16 insulin Phase 2
17 Insulin, Globin Zinc Phase 2
18 Antihypertensive Agents Phase 2
19 Pharmaceutical Solutions Phase 2

Interventional clinical trials:

(show all 12)
# Name Status NCT ID Phase Drugs
1 A Study of Octreotide Depot vs Saline Control in Pediatric Hypothalamic Obesity Patients Completed NCT00171613 Phase 4 Octreotide
2 Pediatric Hypothalamic Obesity Completed NCT00076362 Phase 4 Sandostatin LAR
3 Glucagon-Like Peptide-1 Agonist Effects on Energy Balance in Hypothalamic Obesity Completed NCT02664441 Phase 3 Exenatide;placebo
4 Multicentre Double-blind Randomized Clinical Trial Assessing Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy Completed NCT02860923 Phase 3 Exenatide;Placebo
5 Effects of Exenatide on Hypothalamic Obesity Completed NCT01061775 Phase 1, Phase 2 Exenatide
6 Combined Diazoxide and Metformin Therapy in Children With Hypothalamic Obesity Secondary to Craniopharyngioma: A Pilot Study Completed NCT00892073 Phase 2 Diazoxide;Metformin
7 Effects of Exenatide on Body Weight in Patients With Hypothalamic Obesity Completed NCT01484873 Phase 2 Exenatide
8 Intranasal Oxytocin to Promote Weight Loss in Children, Adolescents, and Adults With Brain Tumors and Hypothalamic Obesity Syndrome Active, not recruiting NCT02849743 Phase 2 Syntocinon;Placebo (for Syntocinon)
9 A Phase 2, Open-Label 20-Week Study to Evaluate the Safety and Efficacy of Setmelanotide in Subjects With Hypothalamic Obesity Not yet recruiting NCT04725240 Phase 2 Setmelanotide
10 Effects of Exenatide on Obesity and/or Diabetes Mellitus Due to Hypothalamic Damage Unknown status NCT01783717 Exenatide
11 Individual Nutritional Support at Home for Patients With Hypothalamic Obesity: Efficacy on Eating Behavior, Physical Activity, Physical Abilities, Weight Gain and Quality of Life Completed NCT03673813
12 Deep Brain Stimulation for Hypothalamic Obesity: A Surgical & Neuroimaging Study Withdrawn NCT03708913

Search NIH Clinical Center for Hypothalamic Obesity

Genetic Tests for Hypothalamic Obesity

Anatomical Context for Hypothalamic Obesity

MalaCards organs/tissues related to Hypothalamic Obesity:

40
Pituitary, Hypothalamus, Brain, Testes, Liver, Adrenal Gland, Bone

Publications for Hypothalamic Obesity

Articles related to Hypothalamic Obesity:

(show top 50) (show all 391)
# Title Authors PMID Year
1
Hypothalamic Obesity: 4 Years of the International Registry of Hypothalamic Obesity Disorders. 61 20
30296362 2018
2
Hypothalamic obesity in children: pathophysiology to clinical management. 20 61
25781673 2015
3
Hypothalamic obesity in children. 20 61
22577758 2012
4
Postoperative and Long-Term Endocrinologic Complications of Craniopharyngioma. 61
33794526 2021
5
The neurotherapeutic role of a selenium-functionalized quinoline in hypothalamic obese rats. 61
33740091 2021
6
MRI measures of hypothalamic injury are associated with glucagon-like peptide-1 receptor agonist treatment response in people with hypothalamic obesity. 61
33651438 2021
7
A phase 3 randomized clinical trial using a once-weekly glucagon-like peptide-1 receptor agonist in adolescents and young adults with hypothalamic obesity. 61
33026160 2021
8
Whole-body vibration promotes lipid mobilization in hypothalamic obesity rat. 61
33202347 2021
9
Novel predictive scoring system for morbid hypothalamic obesity in patients with pediatric craniopharyngioma. 61
32888069 2021
10
Pharmacotherapy in pediatric obesity: current evidence and landscape. 61
33186194 2021
11
Alpha-Melanocyte-Stimulating Hormone is Elevated in Hypothalamic Obesity Associated with Childhood Craniopharyngioma. 61
33491320 2021
12
Vagotomy associated with splenectomy reduces lipid accumulation and causes kidneys histological changes in rats with hypothalamic obesity. 61
33624722 2021
13
Cardiac remodeling in patients with childhood-onset craniopharyngioma-results of HIT-Endo and KRANIOPHARYNGEOM 2000/2007. 61
33459867 2021
14
Case Report: SARS-CoV-2 Infection in a Child With Suprasellar Tumor and Hypothalamic-Pituitary Failure. 61
33796066 2021
15
Cardiac autonomic dysfunction is associated with hypothalamic damage in patients with childhood-onset craniopharyngioma. 61
33591998 2021
16
Obstructive sleep apnea in children with hypothalamic obesity: Evaluation of possible related factors. 61
32986303 2020
17
Liraglutide 3mg as a weight-loss strategy after failed bariatric surgery in a patient with hypothalamic obesity following craniopharyngioma. 61
31362076 2020
18
Management of Hypothalamic Obesity. 61
32741487 2020
19
Stereotactic MRI-guided laser interstitial thermal therapy for extratemporal lobe epilepsy. 61
32777090 2020
20
Methylphenidate improves weight control in childhood brain tumor survivors with hypothalamic obesity. 61
32383818 2020
21
DUODENAL-JEJUNAL BYPASS REDUCES LIPID ACCUMULATION IN THE BROWN ADIPOSE TISSUE OF HYPOTHALAMIC OBESE RATS. 61
32667527 2020
22
Bariatric Surgery for Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy: a Matched Case-Control Study. 61
31955372 2020
23
Metabolic features and changes in glucose-induced serum glucagon-like peptide-1 levels in children with hypothalamic obesity. 61
29389666 2020
24
Quality of life, hypothalamic obesity, and sexual function in adulthood two decades after primary gross-total resection for childhood craniopharyngioma. 61
31222446 2020
25
The advantages and disadvantages of sleeve gastrectomy; clinical laboratory to bedside review. 61
32154399 2020
26
Experiences with Glucagon-Like Peptide-1 Receptor Agonist in Children with Acquired Hypothalamic Obesity. 61
32781455 2020
27
The Diagnosis and Treatment of Craniopharyngioma. 61
31678973 2020
28
Diagnosis, Background, and Treatment of Hypothalamic Damage in Craniopharyngioma. 61
32580186 2020
29
Ommaya Reservoir System for the Treatment of Cystic Craniopharyngiomas: Surgical Results in a Series of 11 Adult Patients and Review of the Literature. 61
31400528 2019
30
Preservation of Hypothalamic Function with Endoscopic Endonasal Resection of Hypothalamus-Invaded Craniopharyngiomas. 61
31398519 2019
31
Laparoscopic Sleeve Gastrectomy on Severe Obesity after Intracranial Germinoma Treatment: A Case Report. 61
31776301 2019
32
Craniopharyngioma. 61
31699993 2019
33
Pituitary disease in pediatric brain tumor survivors. 61
31131647 2019
34
A comprehensive diagnostic approach to detect underlying causes of obesity in adults. 61
30821060 2019
35
Management of hypothalamic disease in patients with craniopharyngioma. 61
30614015 2019
36
Vertical Sleeve Gastrectomy Attenuates Hedonic Feeding Without Impacting Alcohol Drinking in Rats. 61
30740914 2019
37
Detailed assessment of hypothalamic damage in craniopharyngioma patients with obesity. 61
30181653 2019
38
Pathophysiology and Individualized Treatment of Hypothalamic Obesity Following Craniopharyngioma and Other Suprasellar Tumors: A Systematic Review. 61
30247642 2019
39
Metabolic syndrome is a sequela of radiation exposure in hypothalamic obesity among survivors of childhood brain tumors. 61
30530528 2019
40
Hypothalamic Obesity Treatment Demands Thinking Outside the Box. 61
30474263 2019
41
Hypothalamic Obesity: Prologue and Promise. 61
30884480 2019
42
Treatment of Hypothalamic Obesity with Dextroamphetamine: A Case Series. 61
30844799 2019
43
ROHHAD Syndrome, a Rare Cause of Hypothalamic Obesity: Report of Two Cases 61
29553042 2018
44
Interventions for the Treatment of Craniopharyngioma-Related Hypothalamic Obesity: A Systematic Review. 61
29945001 2018
45
Childhood Craniopharyngioma: A 22-Year Challenging Follow-Up in a Single Center. 61
29959763 2018
46
Ventriculoscopic Surgery for Cystic Retrochiasmatic Craniopharyngiomas: Indications, Surgical Technique, and Short-Term Patient Outcomes. 61
29048572 2018
47
From appetite setpoint to appetition: 50years of ingestive behavior research. 61
29305256 2018
48
The development of hypothalamic obesity in craniopharyngioma patients: A risk factor analysis in a well-defined cohort. 61
29314661 2018
49
Clinical study on microsurgical treatment for craniopharyngioma in a single consecutive institutional series of 335 patients. 61
29501046 2018
50
Hepatopulmonary syndrome caused by hypothalamic obesity and nonalcoholic fatty liver disease after surgery for craniopharyngioma: a case report. 61
29609450 2018

Variations for Hypothalamic Obesity

Expression for Hypothalamic Obesity

Search GEO for disease gene expression data for Hypothalamic Obesity.

Pathways for Hypothalamic Obesity

GO Terms for Hypothalamic Obesity

Cellular components related to Hypothalamic Obesity according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.35 RETN LEP INS IGF1 GHRH
2 extracellular region GO:0005576 9.1 RETN LEPR LEP INS IGF1 GHRH

Biological processes related to Hypothalamic Obesity according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.8 LEP INS IGF1 GHRH
2 positive regulation of MAPK cascade GO:0043410 9.63 LEP INS IGF1
3 glucose metabolic process GO:0006006 9.61 LEP INS
4 positive regulation of cytokine production GO:0001819 9.61 LEP INS
5 negative regulation of autophagy GO:0010507 9.6 LEPR LEP
6 T cell differentiation GO:0030217 9.59 LEPR LEP
7 positive regulation of glucose import GO:0046326 9.58 INS IGF1
8 activation of protein kinase B activity GO:0032148 9.58 INS IGF1
9 positive regulation of mitotic nuclear division GO:0045840 9.57 INS IGF1
10 positive regulation of insulin receptor signaling pathway GO:0046628 9.56 LEP INS
11 positive regulation of glycolytic process GO:0045821 9.55 INS IGF1
12 negative regulation of gluconeogenesis GO:0045721 9.54 LEPR INS
13 glucose homeostasis GO:0042593 9.54 LEPR LEP INS
14 positive regulation of glycogen biosynthetic process GO:0045725 9.52 INS IGF1
15 energy reserve metabolic process GO:0006112 9.51 LEPR LEP
16 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.5 LEP INS IGF1
17 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.48 IGF1 GHRH
18 leptin-mediated signaling pathway GO:0033210 9.43 LEPR LEP
19 sexual reproduction GO:0019953 9.4 LEPR LEP
20 negative regulation of feeding behavior GO:2000252 9.26 RETN INS
21 bone mineralization involved in bone maturation GO:0035630 9.16 LEP IGF1
22 bone growth GO:0098868 8.96 LEPR LEP
23 regulation of bone remodeling GO:0046850 8.62 LEPR LEP

Molecular functions related to Hypothalamic Obesity according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 insulin receptor binding GO:0005158 9.26 INS IGF1
2 insulin-like growth factor receptor binding GO:0005159 9.16 INS IGF1
3 hormone activity GO:0005179 9.02 RETN LEP INS IGF1 GHRH
4 peptide hormone receptor binding GO:0051428 8.96 LEP GHRH

Sources for Hypothalamic Obesity

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....